MX2022012441A - Terapeuticos y metodos de tratamiento para coronavirus. - Google Patents

Terapeuticos y metodos de tratamiento para coronavirus.

Info

Publication number
MX2022012441A
MX2022012441A MX2022012441A MX2022012441A MX2022012441A MX 2022012441 A MX2022012441 A MX 2022012441A MX 2022012441 A MX2022012441 A MX 2022012441A MX 2022012441 A MX2022012441 A MX 2022012441A MX 2022012441 A MX2022012441 A MX 2022012441A
Authority
MX
Mexico
Prior art keywords
coronavirus
therapeutics
treatment methods
multimers
treating
Prior art date
Application number
MX2022012441A
Other languages
English (en)
Inventor
Douglas A Hamilton
Ghania Chikh
Original Assignee
Vasomune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasomune Therapeutics Inc filed Critical Vasomune Therapeutics Inc
Publication of MX2022012441A publication Critical patent/MX2022012441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a compuestos de formula (I) los cuales son de forma multimérica de un péptido de unión monomérica linealmente unido a porciones de PEG para formar multímeros y su uso en el tratamiento o prevención de infecciones por coronavirus y Síndrome de angustia respiratoria aguda.
MX2022012441A 2020-04-06 2021-04-05 Terapeuticos y metodos de tratamiento para coronavirus. MX2022012441A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063005981P 2020-04-06 2020-04-06
PCT/US2021/025819 WO2021207099A2 (en) 2020-04-06 2021-04-05 Coronavirus therapeutics and treatment methods

Publications (1)

Publication Number Publication Date
MX2022012441A true MX2022012441A (es) 2023-01-19

Family

ID=78024114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012441A MX2022012441A (es) 2020-04-06 2021-04-05 Terapeuticos y metodos de tratamiento para coronavirus.

Country Status (12)

Country Link
US (1) US20230028130A1 (es)
EP (1) EP4132491A4 (es)
JP (1) JP7344406B2 (es)
KR (1) KR20220164503A (es)
CN (1) CN115666543A (es)
AU (1) AU2021251096B2 (es)
BR (1) BR112022020182A2 (es)
CA (1) CA3171449A1 (es)
IL (1) IL296446A (es)
MX (1) MX2022012441A (es)
WO (1) WO2021207099A2 (es)
ZA (1) ZA202210311B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005361A1 (en) * 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
US8822409B2 (en) * 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
DK2983695T3 (da) * 2013-04-11 2019-09-02 Sunnybrook Res Inst Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister
JP7107968B2 (ja) * 2017-01-13 2022-07-27 ヴァゾミューン セラピューティクス インコーポレイテッド 血管新生を促進する薬剤ならびにその方法および使用

Also Published As

Publication number Publication date
CA3171449A1 (en) 2021-10-14
ZA202210311B (en) 2023-06-28
CN115666543A (zh) 2023-01-31
AU2021251096B2 (en) 2023-09-21
JP2023515273A (ja) 2023-04-12
JP7344406B2 (ja) 2023-09-13
WO2021207099A3 (en) 2021-11-18
US20230028130A1 (en) 2023-01-26
EP4132491A2 (en) 2023-02-15
EP4132491A4 (en) 2024-05-29
AU2021251096A1 (en) 2022-11-10
KR20220164503A (ko) 2022-12-13
IL296446A (en) 2022-11-01
BR112022020182A2 (pt) 2022-11-22
WO2021207099A2 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
MX367541B (es) Inhibidores de papd5 y papd7 para tratar la infeccion por hepatitis b.
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
RS52537B (en) ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA202190473A3 (ru) Противовирусная терапия
BR112013020042A2 (pt) inibidores de vírus da hepatite c
ES2572329A2 (es) Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
MX2022010874A (es) Lactoferrina de uso oral con accion antiviral.
WO2011072247A8 (en) Pathogen restriction factors
RU2011140057A (ru) Способ профилактики и лечения повышенной проницаемости
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
CY1121924T1 (el) Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα
PH12020550436A1 (en) NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
MX2022011231A (es) Inhibidor de cxcr4 para el tratamiento del sindrome de dificultad respiratoria aguda e infecciones virales.
CY1124507T1 (el) Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων
MX2022012441A (es) Terapeuticos y metodos de tratamiento para coronavirus.
EA201791525A2 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
MY170991A (en) Dosing regimens of celgosivir for the treatment of dengue
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
BR112012024522A2 (pt) combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio